Clinical Trial Supply Services

Experic offers a consultative and collaborative approach to technical transfer and process development based on a foundation of deep scientific knowledge and the ability to solve problems and facilitate scale-up. Process development activities are augmented with analytical services, provided by qualifi...

Experic  provides a variety of services to support Phase 3 to commercial-scale process transitions to create a customized solution for your specialty, niche, orphan, or combination product, or support novel pharmaceutical particle engineering technologies. Build-to-suit dedicated suites, a flexible...

With a team of experienced scientists and a robust toolbox of analytical techniques, Experic can support the life cycle of your oral solid dose and/or inhalation pharmaceutical products. Our laboratory staff provides comprehensive analytical solutions to support the entire spectrum of development and manuf...

Experic Expands Capabilities to Manufacture Highly Potent Drug Products

In today’s biopharmaceutical landscape, financial markets are tighter while speed to market remains a critical factor when making development decisions. Increasingly, biopharmaceutical companies are having to make tough choices when prioritizing development of investigational products in their pipelines. Working with a contract development and manufacturing organization (CDMO), however, can help stakeholders ensure that the design of a product’s development program is efficient and appropriate for the stage/phase of development. This article will address how a biopharmaceutical company can leverage the collaborative efforts with their CMDO partner to understand the implications of certain key development decisions. We will also discuss a few types of decisions companies may want to avoid which may preserve cash or reduce costs in the short term but can have unwelcome effects later.